| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/85411 |
| P698 | PubMed publication ID | 11231618 |
| P2093 | author name string | Liggett SB | |
| P2860 | cites work | Initial sequencing and analysis of the human genome | Q21045365 |
| A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms | Q28203288 | ||
| Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group | Q28371563 | ||
| A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors | Q33901100 | ||
| Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism | Q34144158 | ||
| The predictive power of haplotypes in clinical response | Q34189871 | ||
| Heterogeneity of therapeutic responses in asthma | Q34255472 | ||
| Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness | Q37248530 | ||
| Association of beta(2)-adrenoreceptor variants with bronchial hyperresponsiveness. | Q54062682 | ||
| Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment | Q77883189 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 281-283 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Pharmacogenetic applications of the Human Genome project | |
| P478 | volume | 7 |
| Q37000342 | A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure |
| Q34872068 | A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure |
| Q58119331 | ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure |
| Q50481495 | Absence of COCH mutations in patients with Meniere disease. |
| Q34662042 | Can certain genotypes predispose to poor asthma control in children? A pharmacogenetic study of 9 candidate genes in children with difficult asthma. |
| Q36626785 | Current directions in chemotherapy for colorectal cancer |
| Q38430805 | Differential connectivity of gene regulatory networks distinguishes corticosteroid response in asthma |
| Q88235319 | Genetic Vulnerability of GPCRs: A Call to Action |
| Q34360424 | Identification and functional characterization of alpha(2)-adrenoceptor polymorphisms |
| Q35102211 | Implications of pharmacogenetics for individualizing drug treatment and for study design |
| Q34569946 | Metronomic scheduling: the future of chemotherapy? |
| Q92675086 | Novel phylogenetic methods are needed for understanding gene function in the era of mega-scale genome sequencing |
| Q36433595 | Overview of the pharmacogenetics of asthma treatment. |
| Q35689150 | Personalized psychiatry: a realistic goal |
| Q34481324 | Pharmacogenetic tactics and strategies: implications for paediatrics |
| Q34574028 | Pharmacogenetics: the ethical context |
| Q35164676 | Pharmacogenomic considerations in drug delivery |
| Q24561997 | Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects |
| Q38290459 | Recognition of T*G mismatched base pairs in DNA by stacked imidazole-containing polyamides: surface plasmon resonance and circular dichroism studies |
| Q40173309 | Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line |
| Q55004054 | Sequencing of exons 4, 5, 12 of COCH gene in patients with postlingual sensorineural hearing loss accompanied by vestibular lesion. |
| Q53473999 | The pharmacogenetics of asthma and allergic disease |
Search more.